Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | REN | P00797 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22197757 | 0.96 | C5AR1 (0.51) | C5AR1AGTR2AGTR1MC4REPHA2 | |
| SCHEMBL22912577 | 0.95 | AGTR2 (0.53) | C5AR1AGTR2AGTR1MC4REPHA2 | |
| SCHEMBL22197758 | 0.91 | C5AR1 (0.50) | C5AR1AGTR2AGTR1MC4RAPLNR | |
| Talfirastide SCHEMBL15926158 | 0.90 | AGTR1 (0.59) | C5AR1AGTR2AGTR1MC4REPHA2 | |
| SCHEMBL18970524 | 0.89 | C5AR1 (0.55) | C5AR1AGTR2AGTR1MC4REPHA2 | |
| [Val5] - Angiotensin Ii SCHEMBL29551599 | 0.89 | AGTR2 (0.64) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| SCHEMBL29701258 | 0.87 | AGTR2 (0.55) | C5AR1AGTR2AGTR1MC4REPHA2 | |
| SCHEMBL7052378 | 0.87 | AGTR2 (0.65) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| SCHEMBL29972916 | 0.86 | AGTR1 (0.62) | C5AR1AGTR2AGTR1EPHA2F2 | |
| SCHEMBL9510693 | 0.86 | AGTR1 (0.60) | C5AR1AGTR2AGTR1MC4REPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024578-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | UNIVERSITY COLLEGE DUBLIN (IE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024578-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | ACE, AGT, ACE2 | C5AR1 306/4885AGTR2 6/4885AGTR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.